ARIXTRA 7.5 MG / 0.6 ML
FONDAPARINUX SODIUM : 7.5 MG / 0.6 ML · DIN 02258056 · ASPEN PHARMACARE CANADA INC.
Health Canada status: MARKETED
What is ARIXTRA?
ARIXTRA 7.5 MG / 0.6 ML contains FONDAPARINUX SODIUM : 7.5 MG / 0.6 ML. It is listed in the Health Canada Drug Product Database under DIN 02258056, held by ASPEN PHARMACARE CANADA INC., supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 17-Jul-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ARIXTRA used for?
ARIXTRA® (fondaparinux sodium, injection) is indicated for: Prophylaxis of venous thromboembolic events (VTE) for up to one month post-surgery in patients undergoing orthopedic surgeries of the lower limbs such as hip fracture, knee surgery or hip replacement surgery. Prophylaxis of venous thromboembolic events (VTE) in patients undergoing abdominal surgery who are at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery. Treatment of Acute Deep Vein Thrombosis (DVT) and treatment of Acute Pulmonary Embolism (PE). Management of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) for the prevention of death and subsequent myocardial infarction. Management of ST segment elevation myocardial infarction (STEMI) for the prevention of death and myocardial reinfarction in patients who are managed with thrombolytics or who initially are to receive no form of reperfusion therapy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02258056 |
|---|---|
| Brand name | ARIXTRA |
| Generic / active ingredient | FONDAPARINUX SODIUM : 7.5 MG / 0.6 ML |
| Manufacturer | ASPEN PHARMACARE CANADA INC. |
| Strength | 7.5 MG / 0.6 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | B01AX05 FONDAPARINUX |
| AHFS class | 20:12.04.92 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Jul-2018 |
| Original market date | 2008-04-17 00:00:00 |
How is it stored and handled?
If ARIXTRA® is added to a 0.9% saline minibag it should be infused immediately, but can be stored between 15-30°C for up to 24 hours.
How is it supplied?
Package of 10: 2.5 mg ARIXTRA® in pre-filled 0.5 mL single use syringe; 5 mg* ARIXTRA® in 0.4 mL single use pre-filled syringe; 7.5 mg ARIXTRA® in 0.6 mL single use pre-filled syringe; 10 mg* ARIXTRA® in 0.8 mL single use pre-filled syringe.
What can be used instead?
Other Canadian products sharing ATC code B01AX05 FONDAPARINUX. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ARIXTRA | 2.5 MG / 0.5 ML | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 02245531 |
| FONDAPARINUX SODIUM INJECTION | 2.5 MG / 0.5 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02406853 |
| FONDAPARINUX SODIUM INJECTION | 7.5 MG / 0.6 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02406896 |
| ARIXTRA | 10 MG / 0.8 ML | SOLUTION | ASPEN PHARMACARE CANADA INC. | DORMANT | DIN 02451719 |
| ARIXTRA | 5 MG / 0.4 ML | SOLUTION | ASPEN PHARMACARE CANADA INC. | DORMANT | DIN 02451700 |
| FONDAPARINUX SODIUM INJECTION | 10 MG / 0.8 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02406918 |
| FONDAPARINUX SODIUM INJECTION | 5 MG / 0.4 ML | SOLUTION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02406888 |
Who else supplies FONDAPARINUX worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. FONDAPARINUX appears in 32 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.